Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements

Executive Summary

Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process
Advertisement

Related Content

First-Cycle Approvals May Rise For Second Consecutive Year – Parexel Report
Drugs With Better Sales Have Better Development Times, Study Finds
Drugs With Better Sales Have Better Development Times, Study Finds
Tri-Agency Oncology Biomarker Initiative Commences With PET Scan Study
Advertisement
UsernamePublicRestriction

Register

PS047474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel